Sunitinib malate in patients with advanced hepatocellular carcinoma (HCC) who progressed under therapy with sorafenib
M Wörns, H Schulze-Bergkamen, A Teufel, M Schuchmann, C Düber, G Otto, PR Galle, A Weinmann · Zeitschrift für Gastroenterologie · 2009 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: For patients (pts) with advanced HCC who progressed under therapy with sorafenib, no established second-line therapy exists. Three phase II studies have investigated the safety and efficacy of sunitinib malate, another multityrosine kinase inhibitor targeting VEGFR-1,-2,-3, PDGFR-α, -ß, KIT, FLT3 and RET, as first-line therapy in advanced HCC. Based on promising data from the sequential use of both drugs in renal cell carcinoma, we treated pts with advanced HCC and progression under sorafenib treatment with sunitinib (off label-use). Methods: From January to October 2008, 9 pts were treated with 37.5mg sun…
